182 Highly potent fully human anti-VISTA antibodies – a new target checkpoint inhibitor against immunosuppressive myeloid cells
Sign Up to like & getrecommendations! Published in 2020 at "Journal for ImmunoTherapy of Cancer"
DOI: 10.1136/jitc-2020-sitc2020.0182
Abstract: Background V-domain Immunoglobulin Suppressor of T cell Activation (VISTA/PD-1H) is a B7 family ligand expressed on circulating and intratumoural myeloid cells as well as Treg and NK cells. It has been shown to inhibit T… read more here.
Keywords: myeloid cells; anti; vista antibodies; anti vista ... See more keywords
Rationally targeted anti-VISTA antibody that blockades the C-C’ loop region can reverse VISTA immune suppression and remodel the immune microenvironment to potently inhibit tumor growth in an Fc independent manner
Sign Up to like & getrecommendations! Published in 2022 at "Journal for Immunotherapy of Cancer"
DOI: 10.1136/jitc-2021-003382
Abstract: Background Despite significant progress in cancer immunotherapy in recent years, resistance to existing immune checkpoint therapies (ICT) is common. V-domain Ig suppressor of T cell activation (VISTA), a predominantly myeloid immune checkpoint regulator, represents a… read more here.
Keywords: anti vista; hmbd 002; vista; vista antibody ... See more keywords
VISTA targeting of T-cell quiescence and myeloid suppression overcomes adaptive resistance.
Sign Up to like & getrecommendations! Published in 2022 at "Cancer immunology research"
DOI: 10.1158/2326-6066.cir-22-0116
Abstract: VISTA is a premier target for cancer treatment due to its broad expression in many cancer types and enhanced expression upon development of adaptive immune checkpoint resistance. In the CT26 colorectal cancer model, monotherapy of… read more here.
Keywords: cell; adaptive resistance; quiescence; anti vista ... See more keywords